For tens of thousands of women in England, a simple symptom — postmenopausal bleeding — triggers a medical journey that often ends in a painful, invasive examination. Now, an AI-powered blood test being trialled by the NHS could change that entirely.
How the PinPoint AI blood test works for womb cancer detection
The test, developed by Leeds-based PinPoint Data Science, uses machine learning to analyse around 30 markers in a patient's blood sample. It then classifies the woman as low, elevated, or high risk for womb cancer — also known as endometrial cancer.
According to The Guardian, the test costs roughly £30 and provides clinicians with a risk score that fits within existing NHS cancer referral pathways. The idea is simple: if the test shows low risk, many women could avoid the need for a hysteroscopy — a procedure where a camera is inserted into the womb — or an endometrial biopsy.
Why this matters for 90,000 women referred each year
Around 90,000 postmenopausal women in England are referred by their GP each year after reporting heavy bleeding. Of those, only about 10,000 are actually diagnosed with womb cancer. That means roughly 80,000 women undergo invasive checks unnecessarily — procedures that can be painful, anxiety-inducing, and emotionally draining.
For women who are already anxious about a potential cancer diagnosis, the prospect of a painful internal examination adds another layer of distress. A simple blood test could spare them that trauma entirely.
The scale of womb cancer in England
Womb cancer is the fourth most common cancer in women in the UK. Around 10,000 women are diagnosed annually, and approximately 2,700 die from the disease each year. Early detection is critical — survival rates are high when the cancer is caught early, but symptoms like postmenopausal bleeding are often dismissed or delayed.
The current standard of care involves an ultrasound scan followed by a hysteroscopy and biopsy if abnormalities are found. While effective, the invasive nature of these procedures can deter some women from seeking help promptly.
Who could benefit most from the AI blood test
The women most likely to benefit are those classified as low risk by the PinPoint test. For them, the blood test could provide reassurance without the need for further invasive procedures. Those classified as elevated or high risk would still proceed to standard diagnostic pathways — but with a clearer, faster understanding of their situation.
For healthcare providers, the test could reduce pressure on gynaecology services, shorten waiting times, and allow resources to be directed toward patients who need them most.
What NHS officials and experts are saying
PinPoint Data Science has stated that the test gives clinicians a risk score for use within existing cancer referral pathways. The company has not yet published large-scale trial data, but early results have been described as promising by those involved in the rollout.
The Guardian reports that several NHS hospitals are preparing to use the test, though full details of the trial design and expected timeline have not been disclosed. The NHS has not issued a formal statement on the trial as of this report.
How AI is changing cancer detection in the NHS
The PinPoint test is part of a broader push by the NHS to integrate artificial intelligence into cancer diagnostics. Similar AI-powered blood tests are being developed for ovarian, lung, and colorectal cancers. The goal is to catch cancers earlier, reduce invasive procedures, and improve patient experience.
What makes the PinPoint test different is its focus on a specific, high-volume referral pathway — postmenopausal bleeding — where the vast majority of patients turn out not to have cancer. That makes it a strong candidate for reducing unnecessary procedures.
Confirmed facts vs what remains unclear
Confirmed: The PinPoint test analyses 30 blood markers using machine learning. It costs around £30. Several NHS hospitals are preparing to trial it. Around 90,000 women are referred annually for postmenopausal bleeding checks.
Unclear: The exact number of hospitals involved in the trial. The timeline for results or potential wider rollout. The test's accuracy rates in real-world NHS settings. Whether the test will be offered to all referred women or only specific groups.
Risks and balanced view of the AI blood test
While the potential benefits are significant, experts caution that the test is not yet proven at scale. False negatives — where the test misses a cancer — could delay diagnosis and worsen outcomes. False positives could still lead to unnecessary invasive procedures, though likely fewer than the current system.
There are also questions about cost-effectiveness, integration with existing NHS IT systems, and whether the test will be equally accurate across different ethnic groups and age ranges. Independent validation studies are needed before the test can be widely adopted.
Wider trend: AI-powered liquid biopsies in cancer care
The PinPoint test is part of a growing field known as liquid biopsy — detecting cancer from blood samples rather than tissue samples. Companies like Grail and Guardant Health are developing similar tests for multiple cancer types. The NHS has already trialled the Galleri test for detecting dozens of cancers from a single blood draw.
What sets PinPoint apart is its focus on a single cancer type with a clear, high-volume referral pathway. That focus could make it one of the first AI blood tests to be routinely used in NHS gynaecology services.
What women should know about the new test
If you are a postmenopausal woman experiencing heavy bleeding, the current advice remains unchanged: see your GP promptly. The PinPoint test is not yet available to all patients. If the trial is successful, it could become part of standard care within the next few years.
For now, the most important step is not to delay seeking help because of fear of invasive procedures. Early detection saves lives, and the prospect of a simpler test is on the horizon.
What happens next with the NHS trial
The coming months will be critical. If the PinPoint test demonstrates high accuracy in NHS settings, it could be fast-tracked for wider use. If results are mixed, further refinement and larger trials will be needed.
Either way, the direction is clear: the NHS is moving toward less invasive, AI-assisted cancer diagnostics. For the 90,000 women referred each year for womb cancer checks, that shift cannot come soon enough.
Our Take
This is a genuinely promising development — not because AI is a magic solution, but because it targets a specific, high-volume problem where the current approach causes unnecessary suffering. The key will be rigorous, transparent validation. If the PinPoint test works as advertised, it could become a model for how AI is used in cancer care: not replacing doctors, but helping them make faster, smarter decisions — and sparing patients unnecessary pain.
Frequently Asked Questions
What is the PinPoint AI blood test for womb cancer?
It is a blood test developed by PinPoint Data Science that uses machine learning to analyse 30 markers in a blood sample. It classifies women as low, elevated, or high risk for womb cancer, helping doctors decide whether invasive checks are needed.
How much does the NHS AI blood test cost?
PinPoint says the test costs around £30 per patient. It is currently being trialled in several NHS hospitals, so it is not yet available to all patients.
Will the AI blood test replace invasive womb cancer checks?
Not entirely. Women classified as low risk may avoid invasive procedures like hysteroscopy or biopsy. Those classified as elevated or high risk would still proceed to standard diagnostic tests.
When will the PinPoint test be available on the NHS?
There is no confirmed date yet. The test is in the trial phase at several NHS hospitals. If results are positive, wider rollout could follow within a few years.
